Eli Lilly and Company (NYSE: LLY) shares are trading lower after the company ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. The termination is a setback for Lilly’s obesity pipeline among growing investor expectations.
What Happened: Lilly cited strategic business reasons for halting the Phase 2b trial less than a month after launch. The discontinued study planned to enroll 180 overweight patients with type 2 diabetes over 13 months, with results originally expected by October 2026. The primary focus was weight loss — the key secondary measure tracked fat versus muscle loss.
